IDEX Corporation
IEX
$238.54
+2.29%
IDEX Corporation is a diversified industrial manufacturer of pumps, flow meters, valves, and precision fluidic systems serving end markets spanning industrial, fire and safety, life science, and water applications, organized into three reporting segments: Fluid and Metering Technologies, Health and Science Technologies, and Fire and Safety/Diversified Products. The company is best characterized as a high-quality niche compounder rather than a scale player — it holds leading share in many small, specification-driven niches where engineered components and application expertise create switching costs, and it has historically supplemented organic growth with disciplined bolt-on M&A. The current investor debate centers on whether IDEX can sustain its recent reacceleration — Q2 2026 revenue grew 6.4% year over year to $920.6 million with gross margin expanding to 46.4% — against a backdrop of soft industrial capital spending and a stock that has materially outperformed the market over the past year. Attention is also focused on margin durability as the Health and Science segment (the largest at roughly $415 million in the latest period) recovers from the post-pandemic life-science destocking cycle, and on capital deployment given robust free cash flow and a modest leverage profile.…
IEX
IDEX Corporation
$238.54
Related headlines
Investment Opinion: Should I buy IEX Today?
Rating: Hold. IDEX is a high-quality niche compounder with expanding margins and strong cash generation, but at $229.05 it trades at 27.76x trailing and 23.77x forward earnings — a 25–35% premium to machinery peers — for only 6.4% revenue growth, and the analyst average target of $256.57 implies just 12.0% upside. The consensus rating of 1.73 (buy) with 14 analysts and no sell ratings supports holding existing positions, but the risk/reward for new capital is balanced rather than compelling.
The supporting evidence is solid: Q2 2026 revenue grew 6.38% year over year to $920.6 million with sequential gains from $886.9 million in Q1; gross margin expanded to 46.36% from 45.32%; operating margin reached 21.71% versus 19.44% in Q1; trailing free cash flow of $641.5 million yields 4.8% on the market cap; and debt-to-equity of 0.46 with interest coverage near 13.2x provides balance-sheet flexibility. The stock has outperformed the S&P 500 by 22.91 percentage points over one year, and the beta of 0.96 with a -14.49% maximum drawdown makes it a relatively defensive quality holding.
The biggest risks that could invalidate the thesis are a stall in the Health and Science life-science recovery (45% of revenue), multiple compression toward peer multiples (implying 20–25% downside on earnings), and EPS growth that lags margin gains due to interest and other-income drag. This Hold would upgrade to Buy if the forward PE compressed below 20x (roughly $200 per share) or if revenue growth accelerated above 8% with margin expansion continuing; it would downgrade to Sell if revenue growth decelerated below 4% or if gross margin fell back below 44%. Relative to its own history (PE of 32–38x in 2023–2024) the stock is fairly valued to slightly cheap, but relative to peers it remains at a premium — a fair price for quality, not a bargain.
Sign up to view all
IEX 12-Month Price Forecast
IDEX is a quality compounder executing well — margins are expanding, cash flow is strong at $641.5 million trailing, and the balance sheet is conservative — but the stock already reflects much of this at 27.76x trailing earnings and 82.2% of its 52-week range. The 12.0% implied upside to the $256.57 average target is moderate, and the three-month momentum stall (-0.27% over one month) suggests the easy re-rating is done. The base case (55% probability) targets $245–$265 as steady execution justifies the premium, while the bear case (20%) at $195–$215 reflects multiple compression if growth stalls. I would upgrade to bullish if the forward PE compressed below 20x or if Health and Science growth accelerated above 8%; I would downgrade to bearish if gross margin fell below 44% or revenue growth decelerated below 4%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEX Corporation's 12-month outlook, with a consensus price target around $256.57 and implied upside of +7.6% versus the current price.
Average Target
$256.57
0 analysts
Implied Upside
+7.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$215 - $285
Analyst target range
Coverage is broad and constructive, with 14 analysts and a consensus recommendation of "buy" (mean rating of 1.73 on a 1-to-5 scale where 1 is a strong buy). The average target price of $256.57 implies roughly 12.0% upside from the current $229.05, a moderate rather than aggressive expected return that is consistent with a fairly valued quality compounder. The consensus leans clearly bullish — no sell ratings are evident — but the modest implied upside suggests analysts see the stock as close to fairly priced after its 36% one-year run rather than materially undervalued.
The target range of $215.00 to $285.00 is moderately wide, spanning about 30% from low to high, which signals meaningful dispersion in assumptions about the industrial cycle and margin trajectory. The $285 high target implies roughly 24% upside and would require multiple expansion toward the upper end of the historical PE band alongside continued margin gains and a life-science recovery; the $215 low target implies about 6% downside and effectively prices in flat-to-declining margins or a stalled industrial recovery. Recent institutional actions skew positive: Mizuho upgraded to Outperform from Neutral on August 12, 2026, and Oppenheimer, TD Cowen, RBC, Citigroup, Stifel, and Argus have all reiterated Buy/Outperform ratings through the summer and early fall, with DA Davidson the lone Neutral holdout. The pattern of reiterations following Q2 results rather than fresh downgrades supports the view that estimate revisions are stable to positive, though the absence of aggressive target hikes suggests limited near-term catalyst for a re-rating.
Bulls vs Bears: IEX Investment Factors
The bull case currently has stronger evidence: revenue is reaccelerating sequentially, gross margin has expanded 330 basis points year over year, free cash flow yield is a healthy 4.8%, and the balance sheet is conservative with debt-to-equity of 0.46. The bear case rests primarily on valuation — 27.76x trailing PE and 16.23x EV/EBITDA represent a 25–35% premium to machinery peers for 6.4% revenue growth — and on stalling momentum, with the stock flat over one month and up only 2.59% over three months. The single most important tension is whether the Health and Science segment's life-science recovery can sustain the margin expansion; if it does, the premium multiple is justified by quality and cash generation, but if it stalls, the stock's 82.2% positioning within its 52-week range leaves limited cushion. Analyst consensus (1.73 mean rating, $256.57 average target) leans bullish but implies only 12.0% upside, consistent with a fairly valued quality compounder rather than a mispriced opportunity.
Bullish
- Margin expansion accelerating: Gross margin rose to 46.36% in Q2 2026 from 45.32% a year earlier and 43.05% in Q4 2025, while operating margin jumped to 21.71% from 19.44% in Q1. This 330-basis-point sequential operating margin gain shows pricing power and mix improvement are flowing through faster than expected.
- Revenue reaccelerating sequentially: Q2 2026 revenue of $920.6 million grew 6.38% year over year and rose sequentially from $886.9 million in Q1 and $899.1 million in Q4 2025. The steady upward progression suggests the life-science destocking drag is fading and the Health and Science segment ($415.0 million, the largest) is recovering.
- Strong free cash flow and balance sheet: Trailing free cash flow of $641.5 million equates to a 4.8% FCF yield on the $13.4 billion market cap, and Q2 operating cash flow of $200.0 million comfortably funded $23.0 million capex, $53.9 million dividends, and $77.1 million buybacks. Debt-to-equity of 0.46 and interest coverage near 13.2x leave ample room for bolt-on M&A.
- Analyst consensus buy with upside: 14 analysts carry a mean rating of 1.73 (buy) and an average target of $256.57, implying 12.0% upside from $229.05. Recent actions skew positive — Mizuho upgraded to Outperform on August 12, 2026, and Oppenheimer, TD Cowen, RBC, Citigroup, Stifel, and Argus reiterated Buy/Outperform through the summer.
Bearish
- Premium valuation versus sector: At 27.76x trailing PE and 16.23x EV/EBITDA, IDEX trades roughly 25–35% above industrial machinery norms (high-teens to low-20s PE, 11–13x EV/EBITDA). The 3.88x price-to-sales is rich for a company growing revenue at only 6.4%, leaving little room for multiple expansion.
- Momentum has stalled: The stock is down 0.27% over the past month and up only 2.59% over three months, sharply decelerating from the 11.87% six-month and 36.04% one-year gains. Relative strength versus SPY has turned negative over three months (-0.26 points), suggesting the easy re-rating phase is over.
- EPS growth lags margin gains: Q2 2026 EPS of $1.94 rose 11.5% year over year, well below the 330-basis-point operating margin improvement, because interest expense of $15.1 million and a $13.8 million other-income drag absorbed the benefit. This gap limits the pace of forward EPS compounding relative to operating improvements.
- Life-science recovery is the swing factor: Health and Science Technologies at $415.0 million is the largest segment, so consolidated growth hinges on the post-pandemic destocking cycle fully normalizing. If that recovery stalls, the 6.4% revenue growth rate could decelerate toward the low single digits, undermining the forward PE of 23.77x.
IEX Technical Analysis
IDEX is in a sustained uptrend, with the stock up 36.04% over the past year versus a 13.13% gain for the S&P 500 — a relative strength advantage of 22.91 percentage points. At $229.05, the shares sit at roughly 82.2% of the 52-week range of $160.60 to $243.80, positioning them in the upper portion of the band but not at the highs. That positioning is constructive: it reflects persistent accumulation rather than the exhaustion typically seen when a stock pins its 52-week high, and the 27.92% YTD gain (versus 11.45% for SPY) confirms the trend has been durable across the calendar year rather than a single-quarter spike. The one caveat is that the stock has already done a lot of work, leaving less cushion if the industrial cycle disappoints.
Short-term momentum has flattened and diverged from the longer-term trend. The stock is down 0.27% over the past month and up only 2.59% over three months, sharply decelerating from the 11.87% six-month gain and the 36.04% one-year advance. Relative strength tells the same story: +0.75 points versus SPY over one month and -0.26 points over three months, versus +5.42 and +22.91 over six months and one year. This looks like consolidation and mean reversion within an intact uptrend rather than a reversal — the pullback from the October high of $238.62 to $229.05 has been orderly, and the 1-month relative strength has already turned marginally positive even as absolute performance stalled. Volume of roughly 771,000 shares is unremarkable, suggesting no distribution pressure behind the recent drift.
Key technical levels are well defined. Support sits at the 52-week low of $160.60, with a nearer intermediate floor around the $220–$222 area where the stock repeatedly found buyers in September; resistance is the 52-week high of $243.80, with the October swing high of $238.62 as the first hurdle. A breakout above $243.80 would confirm the resumption of the primary uptrend and likely invite momentum-driven flows, while a breakdown below $220 would signal a deeper mean-reversion move toward the $200–$207 zone that contained the stock in April and May. With a beta of 0.96, IDEX is slightly less volatile than the market — a defensive characteristic that supports larger position sizing but also means the stock will not deliver outsized beta-driven upside in a broad rally; the maximum drawdown of -14.49% over the period underscores a relatively contained risk profile.
Beta
0.96
0.96x market volatility
Max Drawdown
-14.5%
Largest decline past year
52-Week Range
$161-$244
Price range past year
Annual Return
+42.9%
Cumulative gain past year
| Period | IEX Return | S&P 500 |
|---|---|---|
| 1m | +3.2% | +0.9% |
| 3m | +2.0% | +4.1% |
| 6m | +11.0% | +7.2% |
| 1y | +42.9% | +12.4% |
| ytd | +33.2% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IEX Fundamental Analysis
Revenue is growing at a mid-single-digit pace with a modestly improving trajectory. Q2 2026 revenue of $920.6 million rose 6.38% year over year from $865.4 million, and the sequential progression from $886.9 million in Q1 and $899.1 million in Q4 2025 shows steady upward momentum rather than a one-off. Segment mix matters: Health and Science Technologies at $415.0 million is the largest contributor, followed by Fluid and Metering at $317.1 million and Fire and Safety at $189.9 million, meaning the life-science recovery is the single most important swing factor for the consolidated growth rate. Consensus estimates of roughly $4.70 billion in forward revenue imply continued mid-single-digit expansion, consistent with a quality industrial compounder rather than a high-growth story.
Profitability is solid and margins are expanding. Q2 2026 net income was $143.4 million on a 15.58% net margin, up from $131.6 million and 15.21% in the prior-year quarter, while gross margin improved to 46.36% from 45.32% a year earlier and from 43.05% in Q4 2025. Operating margin followed the same path, rising to 21.71% in Q2 from 19.44% in Q1 and 20.69% in Q4 2025, and the trailing operating margin of 20.82% is respectable for a diversified machinery business. The one blemish is Q2 EPS of $1.94 versus $1.74 a year ago — a 11.5% increase that lags the margin improvement, reflecting higher interest expense of $15.1 million and a $13.8 million drag in other income/expenses; still, the direction of travel on margins is clearly positive.
Balance sheet and cash generation are strong. Debt-to-equity of 0.46 is conservative for an industrial, the current ratio of 2.86 signals ample liquidity, and interest coverage of roughly 13.2x leaves substantial headroom. Trailing free cash flow of $641.5 million against a $13.4 billion market cap implies an FCF yield of about 4.8%, and Q2 operating cash flow of $200.0 million funded $23.0 million of capex, $53.9 million of dividends, and $77.1 million of buybacks with room to spare. ROE of 12.0% and ROA of 6.84% are moderate rather than spectacular — a function of the capital-intensive, acquisition-built model — but the cash conversion (FCF/operating cash flow of roughly 88.5%) confirms earnings are backed by real cash, reducing dependence on external financing.
Quarterly Revenue
$920600000.0B
2026-06
Revenue YoY Growth
+6.4%
YoY Comparison
Gross Margin
46.4%
Latest Quarter
Free Cash Flow
$641500000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IEX Overvalued?
Because IDEX is solidly profitable — Q2 2026 net income of $143.4 million and trailing EPS positive — the PE ratio is the appropriate primary metric. The stock trades at 27.76x trailing earnings but only 23.77x forward earnings, a roughly 14% compression that implies the market expects meaningful EPS growth; consensus forward EPS of $13.31 versus the current run-rate supports that expectation. On the surface the forward multiple is reasonable for a quality industrial, but the trailing figure is flattered by a low base, and the PEG ratio of -7.12 is not meaningful given the sign of the growth input.
Relative to the broader industrial machinery sector, IDEX screens at a premium on most measures. Its 27.76x trailing PE and 16.23x EV/EBITDA compare with sector norms typically in the high-teens to low-20s for PE and roughly 11–13x for EV/EBITDA, implying a premium of roughly 25–35% on earnings and a similar order of magnitude on EBITDA. The 3.88x price-to-sales and 5.06x EV/sales are also rich for a company growing revenue at 6.4%, though the 46.4% gross margin and 20.8% operating margin are above the diversified-machinery average and go some way toward justifying the premium. The 3.33x price-to-book is the least demanding of the multiples and reflects a business that earns mid-teens returns on equity rather than an asset-light compounder.
Historically, IDEX has traded at considerably richer multiples than it does today. Its PE ratio ranged from roughly 32x to 38x in 2023–2024 and reached 29.2x as recently as Q2 2026, so the current 27.76x sits near the low end of its multi-year band; the price-to-sales ratio of 3.88x is likewise far below the 14x–22x readings recorded across 2023–2025, though those figures appear distorted by share-count or data conventions and should be treated cautiously. The more reliable signal is the PE: at 27.76x trailing and 23.77x forward, the stock is priced for steady execution rather than heroic growth, which limits downside if the industrial cycle merely muddles along but also caps multiple-driven upside unless margin expansion accelerates.
PE
27.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but quantifiable. Interest expense of $15.1 million in Q2 2026 and a $13.8 million drag in other income/expenses absorbed much of the 330-basis-point operating margin gain, limiting EPS growth to 11.5% ($1.94 versus $1.74). Revenue concentration in Health and Science Technologies ($415.0 million of $920.6 million, or 45% of Q2 revenue) means a stall in the life-science destocking recovery would disproportionately hit consolidated growth, which is already only 6.38% year over year. The acquisition-built model produces moderate returns — ROE of 12.0% and ROA of 6.84% — and any debt-funded bolt-on could push debt-to-equity above the current conservative 0.46.
Market and competitive risks center on valuation compression. At 27.76x trailing PE and 16.23x EV/EBITDA, IDEX trades roughly 25–35% above industrial machinery norms, so any deceleration in the 6.4% revenue growth or a pause in margin expansion could trigger a de-rating toward peer multiples, implying 20–25% downside on earnings alone. The beta of 0.96 offers only modest market insulation, and with the stock up 36.04% over one year versus 13.13% for the S&P 500, sector rotation away from industrials would hit a crowded winner. The three-month relative strength versus SPY has already turned negative (-0.26 points), and the absence of aggressive analyst target hikes after Q2 suggests limited near-term re-rating catalyst.
A worst-case scenario would combine a stalled life-science recovery, flat industrial capital spending, and multiple compression toward the low end of the historical PE band. The 52-week low of $160.60 represents 29.9% downside from $229.05, while the analyst low target of $215.00 implies a milder 6.1% decline. A realistic adverse path — revenue growth decelerating toward low single digits and the PE compressing from 27.76x toward the low-20s — could take the stock to the $180–$200 zone, a loss of roughly 13–21%, with the full 52-week low (-29.9%) reserved for a genuine industrial recession. The maximum drawdown of -14.49% over the past 180 days suggests the stock's typical correction is contained, but a valuation-led de-rating could exceed that historical range.
FAQ
The most severe risk is valuation compression: at 27.76x trailing PE and 16.23x EV/EBITDA, a de-rating toward peer multiples could erase 20–25% of value even if earnings hold. Second is segment concentration — Health and Science at $415.0 million (45% of Q2 revenue) means a stalled life-science recovery would disproportionately hit the 6.38% consolidated growth rate. Third is earnings quality: Q2 EPS growth of 11.5% lagged the 330-basis-point operating margin gain because $15.1 million interest expense and a $13.8 million other-income drag absorbed the benefit. Fourth is momentum risk — the stock is flat over one month and up only 2.59% over three months, and a break below $220 support could trigger a mean-reversion move toward $200–$207.
The 12-month forecast has three scenarios: a base case (55% probability) targeting $245–$265 as mid-single-digit growth and margin expansion deliver forward EPS near $13.31, in line with the $256.57 analyst average; a bull case (25%) targeting $270–$285 if the life-science recovery accelerates and gross margin pushes toward 47–48%; and a bear case (20%) targeting $195–$215 if industrial spending softens and the premium multiple compresses. The base case is most likely because it requires only steady execution — revenue growth of 5–7% and gross margin holding at 45.5–46.5% — rather than a major re-rating. The key assumption is that Health and Science revenue growth recovers gradually without a stall.
IDEX is fairly valued relative to its own history but at a premium to peers. The 27.76x trailing PE sits near the low end of its 2023–2024 range of 32–38x, and the 23.77x forward PE implies roughly 14% EPS growth to the $13.31 consensus. However, versus industrial machinery norms of high-teens to low-20s PE and 11–13x EV/EBITDA, IDEX's 16.23x EV/EBITDA and 3.88x price-to-sales represent a 25–35% premium. The market is paying for quality — 46.4% gross margin, 20.8% operating margin, and 4.8% FCF yield — but not for heroic growth. The valuation implies the market expects steady mid-single-digit revenue growth and continued margin expansion; a stall in either would likely compress the multiple toward peer levels.
IDEX offers a balanced risk/reward rather than a compelling bargain. The stock trades at $229.05, 12.0% below the $256.57 analyst average target, with a 1.73 (buy) consensus from 14 analysts and no sell ratings. Upside is supported by 6.38% revenue growth, 46.36% gross margin, and 4.8% free cash flow yield, but the 27.76x trailing PE is a 25–35% premium to machinery peers for mid-single-digit growth. The biggest downside risk is multiple compression toward the analyst low target of $215 (6.1% downside) or the 52-week low of $160.60 (29.9% downside) if the life-science recovery stalls. It is a good buy for long-term investors seeking defensive quality with modest upside, but new capital should wait for a pullback toward $210–$215 or evidence of accelerating Health and Science growth.
IDEX is better suited for long-term holding than short-term trading. Its beta of 0.96 and maximum drawdown of -14.49% indicate contained volatility, but the three-month momentum stall (-0.27% over one month, 2.59% over three months) offers little short-term catalyst, and the 12.0% analyst target upside is modest for a trade. The 1.59% dividend yield with a 44% payout ratio and $641.5 million trailing free cash flow support a multi-year compounding thesis built on margin expansion and bolt-on M&A. A suggested minimum holding period is 2–3 years to capture the life-science recovery and the compounding of mid-single-digit revenue growth with expanding margins, rather than 3–6 months where valuation compression risk dominates.